Biogen Inc’s (NASDAQ:BIIB) base business seems to be worth more than what the Street estimates, and it is possible that investors are not properly valuing royalty streams coming to the company, which contributes 15% of current revenues and 40% of the valuation, according to Wells Fargo.
The Biogen Analyst: Mohit Bansal upgraded the rating for Biogen from Equal Weight to Overweight, while keeping the price target unchanged at $265.
